Lexeo Therapeutics (LXEO) Income from Continuing Operations (2022 - 2026)
Lexeo Therapeutics (LXEO) reported Income from Continuing Operations of 20196000.0 for Q1 2026, up 38.16% on a YoY basis from 14618329.99 in Q1 2025, and up 5.82% sequentially from 21445000.0 in Q4 2025.
Lexeo Therapeutics (LXEO) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Lexeo Therapeutics (LXEO) has 5 years of Income from Continuing Operations data on file, last reported at 20196000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 38.16% year-over-year to 20196000.0; the trailing twelve-month figure through Mar 2026 stood at 88027000.0 (up 19.47% YoY), and the FY2025 full-year result was 222062000.0, down 125.83% from the prior year.
- Income from Continuing Operations advanced to 20196000.0 in Q1 2026, from 21445000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 13441000.0 in Q2 2023 to a low of 32656000.0 in Q1 2025.
- A 5-year average of 21136066.67 and a median of 20283000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations tumbled 82.73% in 2024 and jumped 38.16% in 2026, its largest moves.
- Tracing LXEO's Income from Continuing Operations over 5 years: stood at 14577000.0 in 2022, then climbed by 2.68% to 14187000.0 in 2023, then slumped by 82.73% to 25924000.0 in 2024, then advanced by 17.28% to 21445000.0 in 2025, then advanced by 5.82% to 20196000.0 in 2026.
- Business Quant data shows LXEO's Income from Continuing Operations at 20196000.0 in Q1 2026, 21445000.0 in Q4 2025, and 20283000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Lexeo Therapeutics | 379.94 Mn | 379.94 Mn | - | -20.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.20 Mn |
| Dec 31, 2025 | -21.45 Mn |
| Sep 30, 2025 | -20.28 Mn |
| Jun 30, 2025 | -26.10 Mn |
| Mar 31, 2025 | -32.66 Mn |
| Dec 31, 2024 | -25.92 Mn |
| Sep 30, 2024 | -29.49 Mn |
| Jun 30, 2024 | -21.24 Mn |
| Mar 31, 2024 | -21.68 Mn |
| Dec 31, 2023 | -14.19 Mn |
| Sep 30, 2023 | -20.11 Mn |
| Jun 30, 2023 | -13.44 Mn |
| Mar 31, 2023 | -18.66 Mn |
| Dec 31, 2022 | -14.58 Mn |
| Sep 30, 2022 | -17.06 Mn |